Billionaire Ray Dalio is betting on these 3 stocks

Linde PLC (LIN)

This image has an empty alt attribute; its file name is LIN.jpg

Linde’s industry leadership and core products have helped the company cope with the crisis. The company’s revenue fell in 1Q20, but rose in the second half, reaching pre-pandemic levels in Q3 and exceeding those levels in Q4. The company kept its dividend stable at 96 cents per share – and raised the payout to $ 1.06 per share. This is calculated on an annual basis up to $ 4.24 and gives a yield of 1.7%. The key point here is not moderate profitability, but the company’s confidence in the security of its positions, which allows it to maintain a stable dividend at a time when many colleagues are reducing profit sharing.

Then it’s no wonder that an investor like Dalio would be interested in a company like Linde. In the fourth quarter, the billionaire’s fund collected 20,149 shares worth $ 5.05 million at current prices. LIN continues to pursue its growth strategy to stimulate stable double-digit profit growth, accompanied by upcoming projects, efficiency gains and solid buyouts with its strong balance sheet and cash flows. In addition, the FCF’s solid position provides them with room for mergers and acquisitions, impairments and more. LIN is believed to be ready to continue to surprise investors and exceed expectations and operate as the world’s largest industrial gas company.

BlackRock (BLK)

This image has an empty alt attribute; its file name is BLK.jpg

Next is the world’s largest asset manager. BlackRock has more than $ 8.67 trillion in assets under management. The company is one of the dominant index funds on the US financial scene and reported $ 16.2 billion in revenue last year, with a net profit of $ 4.9 billion.
The latest BlackRock report for the fourth quarter shows its strength as far as can figures: EPS reached $ 10.02 per share, 12% consecutive earnings and 20% annual earnings. Quarterly revenue of $ 4.8 billion increased 17% year on year. BlackRock has achieved all this, even when the crown crisis smoothed out the economy in 1H20.

In the first quarter of this year, BlackRock declared its regular quarterly dividend and increased its payment by 13% to $ 4.13 per ordinary share. The company has kept its dividend reliable for the past 12 years. Not wanting to miss an insurmountable opportunity, the Dalio fund pulled the trigger on 19,917 shares, giving it a new position in BLK. The value of this new addition? More than $ 14 million.

AbbVie (ABBV)

This image has an empty alt attribute; its file name is ABBV.jpg

AbbVie is a major name in the pharmaceutical industry. The company is a manufacturer of Humira, an anti-inflammatory drug used to treat a wide range of chronic diseases, including rheumatoid arthritis, Crohn’s disease and psoriasis. Treatments for psoriasis and rheumatoid arthritis, respectively, last year reported sales of $ 2.3 billion. AbbVie expects these drugs to “fill the gap” in profits when Humira’s patents expire in 2023, with sales of up to $ 20 billion by 2025.

Humira is currently the main driver of AbbVie’s immunological portfolio and provides $ 19.8 billion of the portfolio’s annual revenue of $ 22.2 billion and a significant portion of the company’s total sales. For the full year 2020, in all divisions, AbbVie saw $ 45.8 billion in revenue, with adjusted diluted EPS of $ 10.56.
The company has an 8-year history of maintaining a reliable – and growing – dividend. In the last declaration made this month for payment in May, AbbVie raised the dividend by 10% to $ 1.30 per ordinary share. At $ 5.20 a year, this gives a return of 4.9%. Between the growth trajectory of ABBV’s former Humira portfolio and the broad portfolio of asset catalysts, it is difficult to find a biopharmaceutical company that is better off. position, even with the looming LOE.


 Junior Trader Kameliya Ivanova

Read more:
If you think, we can improve that section,
please comment. Your oppinion is imortant for us.
WARNING: Any news, opinions, research, data or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. Varchev Finance Ltd. expressly disclaims any liability for any lost principal or profits which may arise directly or indirectly from the use of or reliance on such information. Varchev Finance Ltd. may provide information, quotes, references and links to or from other sites and blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the sites, blogs or other sources of information.
Varchev Finance